Oxytocin, 4-L-asparagine-
| Internal ID | fcfd0e37-6851-45ae-8cdb-086bebcf6b3f |
| Taxonomy | Organic acids and derivatives > Carboxylic acids and derivatives > Amino acids, peptides, and analogues > Peptides > Oligopeptides |
| IUPAC Name | 1-[(7S,10S,16S,19R)-19-amino-7,10-bis(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide |
| SMILES (Canonical) | CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CC(=O)N |
| SMILES (Isomeric) | CC[C@H](C)C1C(=O)N[C@H](C(=O)N[C@H](C(=O)NC(CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CC(=O)N |
| InChI | InChI=1S/C42H64N12O12S2/c1-5-21(4)34-41(65)51-28(16-32(45)57)37(61)49-27(15-31(44)56)38(62)52-29(19-68-67-18-24(43)35(59)48-26(39(63)53-34)14-22-8-10-23(55)11-9-22)42(66)54-12-6-7-30(54)40(64)50-25(13-20(2)3)36(60)47-17-33(46)58/h8-11,20-21,24-30,34,55H,5-7,12-19,43H2,1-4H3,(H2,44,56)(H2,45,57)(H2,46,58)(H,47,60)(H,48,59)(H,49,61)(H,50,64)(H,51,65)(H,52,62)(H,53,63)/t21-,24-,25-,26-,27-,28-,29?,30?,34?/m0/s1 |
| InChI Key | VIFAMMRBZBWEID-JOHMJIRDSA-N |
| Popularity | 23 references in papers |
| Molecular Formula | C42H64N12O12S2 |
| Molecular Weight | 993.20 g/mol |
| Exact Mass | 992.42080787 g/mol |
| Topological Polar Surface Area (TPSA) | 450.00 Ų |
| XlogP | -2.90 |
| Atomic LogP (AlogP) | -4.00 |
| H-Bond Acceptor | 15 |
| H-Bond Donor | 12 |
| Rotatable Bonds | 16 |
| SCHEMBL2398841 |
| NS00125978 |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | + | 0.8054 | 80.54% |
| Caco-2 | - | 0.8676 | 86.76% |
| Blood Brain Barrier | - | 0.8500 | 85.00% |
| Human oral bioavailability | - | 0.7714 | 77.14% |
| Subcellular localzation | Mitochondria | 0.5166 | 51.66% |
| OATP2B1 inhibitior | - | 0.7146 | 71.46% |
| OATP1B1 inhibitior | + | 0.8601 | 86.01% |
| OATP1B3 inhibitior | + | 0.9349 | 93.49% |
| MATE1 inhibitior | - | 0.8400 | 84.00% |
| OCT2 inhibitior | - | 0.9250 | 92.50% |
| BSEP inhibitior | + | 0.9367 | 93.67% |
| P-glycoprotein inhibitior | + | 0.7478 | 74.78% |
| P-glycoprotein substrate | + | 0.8815 | 88.15% |
| CYP3A4 substrate | + | 0.7243 | 72.43% |
| CYP2C9 substrate | - | 1.0000 | 100.00% |
| CYP2D6 substrate | - | 0.8018 | 80.18% |
| CYP3A4 inhibition | - | 0.6078 | 60.78% |
| CYP2C9 inhibition | - | 0.8276 | 82.76% |
| CYP2C19 inhibition | - | 0.7647 | 76.47% |
| CYP2D6 inhibition | - | 0.8702 | 87.02% |
| CYP1A2 inhibition | - | 0.9192 | 91.92% |
| CYP2C8 inhibition | + | 0.6848 | 68.48% |
| CYP inhibitory promiscuity | - | 0.9130 | 91.30% |
| UGT catelyzed | + | 0.8000 | 80.00% |
| Carcinogenicity (binary) | - | 0.7300 | 73.00% |
| Carcinogenicity (trinary) | Non-required | 0.6348 | 63.48% |
| Eye corrosion | - | 0.9841 | 98.41% |
| Eye irritation | - | 0.9016 | 90.16% |
| Skin irritation | - | 0.7658 | 76.58% |
| Skin corrosion | - | 0.9134 | 91.34% |
| Ames mutagenesis | - | 0.5900 | 59.00% |
| Human Ether-a-go-go-Related Gene inhibition | - | 0.4358 | 43.58% |
| Micronuclear | + | 0.8900 | 89.00% |
| Hepatotoxicity | - | 0.7573 | 75.73% |
| skin sensitisation | - | 0.8480 | 84.80% |
| Respiratory toxicity | + | 0.8222 | 82.22% |
| Reproductive toxicity | + | 1.0000 | 100.00% |
| Mitochondrial toxicity | + | 0.9125 | 91.25% |
| Nephrotoxicity | - | 0.8161 | 81.61% |
| Acute Oral Toxicity (c) | I | 0.7517 | 75.17% |
| Estrogen receptor binding | + | 0.8737 | 87.37% |
| Androgen receptor binding | + | 0.6578 | 65.78% |
| Thyroid receptor binding | - | 0.5000 | 50.00% |
| Glucocorticoid receptor binding | - | 0.8108 | 81.08% |
| Aromatase binding | + | 0.6674 | 66.74% |
| PPAR gamma | + | 0.7677 | 76.77% |
| Honey bee toxicity | - | 0.7446 | 74.46% |
| Biodegradation | - | 0.8000 | 80.00% |
| Crustacea aquatic toxicity | - | 0.5800 | 58.00% |
| Fish aquatic toxicity | + | 0.8811 | 88.11% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL2581 | P07339 | Cathepsin D | 99.92% | 98.95% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 98.76% | 96.09% |
| CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 98.70% | 97.25% |
| CHEMBL2693 | Q9UIQ6 | Cystinyl aminopeptidase | 98.66% | 97.64% |
| CHEMBL2107 | P61073 | C-X-C chemokine receptor type 4 | 98.55% | 93.10% |
| CHEMBL4203 | Q9HAZ1 | Dual specificity protein kinase CLK4 | 98.05% | 94.45% |
| CHEMBL5103 | Q969S8 | Histone deacetylase 10 | 97.99% | 90.08% |
| CHEMBL4208 | P20618 | Proteasome component C5 | 97.55% | 90.00% |
| CHEMBL4461 | Q9NTG7 | NAD-dependent deacetylase sirtuin 3 | 97.14% | 94.36% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 96.61% | 97.09% |
| CHEMBL4478 | Q00975 | Voltage-gated N-type calcium channel alpha-1B subunit | 95.89% | 97.14% |
| CHEMBL3830 | Q2M2I8 | Adaptor-associated kinase | 95.65% | 83.10% |
| CHEMBL221 | P23219 | Cyclooxygenase-1 | 95.56% | 90.17% |
| CHEMBL206 | P03372 | Estrogen receptor alpha | 95.53% | 97.64% |
| CHEMBL4040 | P28482 | MAP kinase ERK2 | 95.08% | 83.82% |
| CHEMBL3267 | P48736 | PI3-kinase p110-gamma subunit | 94.86% | 95.71% |
| CHEMBL3359 | P21462 | Formyl peptide receptor 1 | 94.66% | 93.56% |
| CHEMBL6175 | Q9H3R0 | Lysine-specific demethylase 4C | 93.98% | 96.69% |
| CHEMBL3108638 | O15164 | Transcription intermediary factor 1-alpha | 93.24% | 95.56% |
| CHEMBL5608 | Q16288 | NT-3 growth factor receptor | 93.06% | 95.89% |
| CHEMBL5845 | P23415 | Glycine receptor subunit alpha-1 | 92.77% | 90.71% |
| CHEMBL2514 | O95665 | Neurotensin receptor 2 | 92.56% | 100.00% |
| CHEMBL4777 | P25929 | Neuropeptide Y receptor type 1 | 92.09% | 96.67% |
| CHEMBL4979 | P13866 | Sodium/glucose cotransporter 1 | 91.74% | 98.24% |
| CHEMBL3837 | P07711 | Cathepsin L | 91.41% | 96.61% |
| CHEMBL1907594 | P30926 | Neuronal acetylcholine receptor; alpha3/beta4 | 91.40% | 97.23% |
| CHEMBL3437 | Q16853 | Amine oxidase, copper containing | 91.26% | 94.00% |
| CHEMBL3310 | Q96DB2 | Histone deacetylase 11 | 91.14% | 88.56% |
| CHEMBL4506 | Q96EB6 | NAD-dependent deacetylase sirtuin 1 | 91.13% | 88.33% |
| CHEMBL1907591 | P30926 | Neuronal acetylcholine receptor; alpha4/beta4 | 90.40% | 100.00% |
| CHEMBL1921 | P47901 | Vasopressin V1b receptor | 90.13% | 92.50% |
| CHEMBL4227 | P25090 | Lipoxin A4 receptor | 89.74% | 100.00% |
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 89.72% | 91.11% |
| CHEMBL3807 | P17706 | T-cell protein-tyrosine phosphatase | 89.71% | 93.00% |
| CHEMBL3892 | Q99500 | Sphingosine 1-phosphate receptor Edg-3 | 89.49% | 97.29% |
| CHEMBL3130 | O00329 | PI3-kinase p110-delta subunit | 88.54% | 96.47% |
| CHEMBL3384 | Q16512 | Protein kinase N1 | 88.16% | 80.71% |
| CHEMBL2069156 | Q14145 | Kelch-like ECH-associated protein 1 | 88.13% | 82.38% |
| CHEMBL242 | Q92731 | Estrogen receptor beta | 88.08% | 98.35% |
| CHEMBL1907605 | P24864 | Cyclin-dependent kinase 2/cyclin E1 | 87.86% | 92.88% |
| CHEMBL5852 | Q96P65 | Pyroglutamylated RFamide peptide receptor | 87.81% | 85.00% |
| CHEMBL2111367 | P27986 | PI3-kinase p110-alpha/p85-alpha | 87.11% | 94.33% |
| CHEMBL2274 | Q9H228 | Sphingosine 1-phosphate receptor Edg-8 | 86.94% | 100.00% |
| CHEMBL4462 | Q8IXJ6 | NAD-dependent deacetylase sirtuin 2 | 86.83% | 90.24% |
| CHEMBL5896 | O75164 | Lysine-specific demethylase 4A | 86.77% | 99.09% |
| CHEMBL3392948 | Q9NP59 | Solute carrier family 40 member 1 | 86.30% | 95.00% |
| CHEMBL1907603 | Q05586 | Glutamate NMDA receptor; GRIN1/GRIN2B | 86.07% | 95.89% |
| CHEMBL268 | P43235 | Cathepsin K | 85.59% | 96.85% |
| CHEMBL5203 | P33316 | dUTP pyrophosphatase | 85.58% | 99.18% |
| CHEMBL340 | P08684 | Cytochrome P450 3A4 | 85.22% | 91.19% |
| CHEMBL1806 | P11388 | DNA topoisomerase II alpha | 84.05% | 89.00% |
| CHEMBL5163 | Q9NY46 | Sodium channel protein type III alpha subunit | 82.78% | 96.90% |
| CHEMBL4198 | P98170 | Inhibitor of apoptosis protein 3 | 82.38% | 97.79% |
| CHEMBL236 | P41143 | Delta opioid receptor | 82.26% | 99.35% |
| CHEMBL2535 | P11166 | Glucose transporter | 82.12% | 98.75% |
| CHEMBL213 | P08588 | Beta-1 adrenergic receptor | 81.72% | 95.56% |
| CHEMBL2073 | P07947 | Tyrosine-protein kinase YES | 81.61% | 83.14% |
| CHEMBL4588 | P22894 | Matrix metalloproteinase 8 | 81.34% | 94.66% |
| CHEMBL1937 | Q92769 | Histone deacetylase 2 | 81.07% | 94.75% |
| CHEMBL4005 | P42336 | PI3-kinase p110-alpha subunit | 80.38% | 97.47% |
Below are displayed all the plants proven (via scientific papers) to contain this
compound!
To see more specific details click the taxa you are interested in.
To see more specific details click the taxa you are interested in.
| There are no matching plants. |
| PubChem | 68625 |
| LOTUS | LTS0044226 |
| wikiData | Q105286812 |